JP Patent

JP2012530135A — ジペプチジルペプチダーゼ−４阻害剤及びピオグリタゾンの併用医薬組成物

Assigned to Merck and Co Inc · Expires 2012-11-29 · 13y expired

What this patent protects

本発明は、ジペプチジルペプチダーゼ−４阻害剤及びピオグリタゾンの固定用量併用剤を含む医薬組成物、かかる医薬組成物の調製法、及びかかる医薬組成物による２型糖尿病の治療法に関する。

USPTO Abstract

本発明は、ジペプチジルペプチダーゼ−４阻害剤及びピオグリタゾンの固定用量併用剤を含む医薬組成物、かかる医薬組成物の調製法、及びかかる医薬組成物による２型糖尿病の治療法に関する。

Drugs covered by this patent

atrasentan-hydrochloride (ATRASENTAN HYDROCHLORIDE)

Patent Metadata

Patent number: JP2012530135A
Jurisdiction: JP
Classification: —
Expires: 2012-11-29
Drug substance claim: No
Drug product claim: No
Assignee: Merck and Co Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.